Cargando…
Clinical use of HD-MTX monotherapy in a rare case of refractory primary bone diffuse large B-cell lymphoma with long-term survival after local radiotherapy: A case report
Primary bone diffuse large B-cell lymphoma (PB-DLBCL) has been rarely reported because of its low incidence. The optimal treatment plan for patients with relapsed/refractory PB-DLBCL remains controversial. In this study, we present a case of a 57-year-old patient with refractory PB-DLBCL to better u...
Autores principales: | Wu, Zhiya, Teng, Yue, Wu, Jianqiu, Zhang, Honglu, Peng, Weiwei, Meng, Cheng, Tang, Weiyan, Feng, Jifeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810803/ https://www.ncbi.nlm.nih.gov/pubmed/36619626 http://dx.doi.org/10.3389/fmed.2022.989590 |
Ejemplares similares
-
Implementation of an Outpatient HD-MTX Initiative
por: Sokol, Kelsey, et al.
Publicado: (2022) -
ML-13 AN ATTEMPT OF RECHALLENGE OF HD-MTX AND MAINTENANCE THERAPY OF MTX FOR PATIENTS WITH PCNSL
por: Yamaguchi, Takashi, et al.
Publicado: (2019) -
PB2315: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZR OR ZRM REGIMEN (ZANUBRUTINIB, RITUXIMAB, METHOTREXATE)
por: Teng, Yue, et al.
Publicado: (2023) -
Real-world efficacy of DA-EPOCH-R/HD-MTX regimen in CD5-positive diffuse large B cell lymphoma: a single-institute analysis
por: Toyama, Kohtaro, et al.
Publicado: (2023) -
Pre‐miR‐27a rs895819 polymorphism and risk of diffuse large B‐cell lymphoma
por: Tang, Weiyan, et al.
Publicado: (2019)